MATTERS ARISING

Management of knee osteoarthritis

I read with great interest Dr Jawad's letter and the authors' reply about the EULAR recommendations for the management of knee osteoarthritis (OA).1

Although most points of criticism were answered by M Dougdas and M Doherty it seems to me that treatment of knee OA with symptomatic slow acting drugs in osteoarthritis (SYSADOA) and cyclooxygenase-2 (COX-2) inhibitors needs to be discussed in a different way in the light of recent publications.

With respect to SYSADOA, the statement that these substances may modify structure has been strengthened by the publication of Register et al, in which glucosamine sulphate (GS) treatment was proved to exert a significant decrease in joint space narrowing compared with placebo during a three year period, indicating the disease modifying effect of GS for the first time. Moreover, symptomatic efficacy was shown using the WOMAC index as an outcome measure.

As a member of the ESCISIT task force I feel free to discuss some of the issues raised by Dr Jawad and to give further arguments for the accuracy of the recommendations developed by the group of European experts.2

As a matter of the ESCISIT task force I feel free to discuss some of the issues raised by Dr Jawad and to give further arguments for the accuracy of the recommendations developed by the group of European experts.2

The symptoms of patients with severe joint space narrowing receiving GS did improve, but this was not associated with slowing down of radiographic structure impairment. Further studies with longer follow up are needed to assess whether these changes are predictive of further clinical progression of osteoarthritis.

The year 2000 meta-analysis of the six best designed trials of GS for osteoarthritis reported two possible limitations among the analysed studies. Firstly, only one study had adequately assured randomised allocation. The second limitation was that authors were often affiliated with the manufacturers of the product tested. Among the six studies analysed, the one reporting the highest quality score reported the smallest effect.

A meta-analysis of seven randomised controlled trials of chondroitin sulphate (CS) in osteoarthritis had shown better pain relief with CS than with placebo at six months, however, no dose effect was noted (for example, 2000 mg and 800 mg/d were similarly effective). A large long term, double blind, randomised controlled trial is needed to confirm the symptomatic benefit of CS in osteoarthritis.

The main advantage of GS and CS is their safety, and they are certainly more safe than non-selective, non-steroidal anti-inflammatory drugs (NSAIDs), especially in their effect on the gastrointestinal tract.

With regards to COX-1 sparing NSAIDs, I agree with Dr Leeb, that there is no evidence for any important differences in efficacy between them and non-selective NSAIDs.3

Systematic reviews have also found no important differences in efficacy between different NSAIDs, but found differences in side effects related to increased doses of NSAIDs and the nature of the NSAID itself.4

The principal benefit of COX-1 sparing NSAIDs is that they produce analgesia and anti-inflammatory effects comparable with those of the non-selective NSAIDs but cause fewer symptomatic gastric and duodenal ulcers and fewer gastrointestinal symptoms.5

The EULAR recommendations need to be revised in the near future.

A M JAWAD
The Royal London Hospital, Bancroft Road, London E1 4DG, UK

Author's reply

I thank Dr Leeb for his interest in my recent letter about the EULAR recommendations.6 The recent large, randomised, placebo controlled, double blind, prospective trial had shown that glucosamine sulphate (GS) treatment resulted in significantly less medial joint space narrowing of the knee, in addition to significant improved pain and disability, which were sustained for the three year duration of the study. However, the general correlation between symptoms and structural changes was poor.7 The symptoms of patients with severe joint space narrowing receiving GS did improve, but this was not associated with slowing down of radiographic structure impairment. Further studies with longer follow up are needed to assess whether these changes are predictive of further clinical progression of osteoarthritis.

The year 2000 meta-analysis of the six best designed trials of GS for osteoarthritis reported two possible limitations among the analysed studies. Firstly, only one study had adequately assured randomised allocation.7 The second limitation was that authors were often affiliated with the manufacturers of the product tested. Among the six studies analysed, the one reporting the highest quality score reported the smallest effect.7

A meta-analysis of seven randomised controlled trials of chondroitin sulphate (CS) in osteoarthritis had shown better pain relief with CS than with placebo at six months; however, no dose effect was noted (for example, 2000 mg and 800 mg/d were similarly effective). A large long term, double blind, randomised controlled trial is needed to confirm the symptomatic benefit of CS in osteoarthritis.

The main advantage of GS and CS is their safety, and they are certainly more safe than non-selective, non-steroidal anti-inflammatory drugs (NSAIDs), especially in their effect on the gastrointestinal tract.

With regards to COX-1 sparing NSAIDs, I agree with Dr Leeb, that there is no evidence for any important differences in efficacy between them and non-selective NSAIDs.7

Systematic reviews have also found no important differences in efficacy between different NSAIDs, but found differences in side effects related to increased doses of NSAIDs and the nature of the NSAID itself.7 The principal benefit of COX-1 sparing NSAIDs is that they produce analgesia and anti-inflammatory effects comparable with those of the non-selective NSAIDs but cause fewer symptomatic gastric and duodenal ulcers and fewer gastrointestinal symptoms.7

The EULAR recommendations need to be revised in the near future.

A M JAWAD
The Royal London Hospital, Bancroft Road, London E1 4DG, UK

Letters to the editor

Fenofibrate: a new treatment for hyperuricaemia and gout?

Allopurinol is the most commonly used drug in the prevention of gout owing to its efficacy and good tolerability. However, some patients still experience hyperuricaemia or gout, or

LETTERS TO THE EDITOR

Fenofibrate: a new treatment for hyperuricaemia and gout?

Allopurinol is the most commonly used drug in the prevention of gout owing to its efficacy and good tolerability. However, some patients still experience hyperuricaemia or gout, or

www.annrheumdis.com

Ann Rheum Dis 2001;60:984–992

Dr Leeb is currently taking part in a trial focused on the disease modifying ability of CS, sponsored by B F LEEB

Lower Austrian Centre for Rheumatology, Stockerau Hospital, A-2000 Stockerau, Landstrasse 18, Austria

leeb.bst@stockerau@aon.at

9 Noack W, Fischer M, Forster KK, Rovatic LC, Setnikar I. Glucosamine sulfa

Ann Rheum Dis 2001;60:984–992

Dr Leeb is currently taking part in a trial focused on the disease modifying ability of CS, sponsored by B F LEEB

Lower Austrian Centre for Rheumatology, Stockerau Hospital, A-2000 Stockerau, Landstrasse 18, Austria

leeb.bst@stockerau@aon.at

Table 1 Effect of the addition and withdrawal of fenofibrate on serum urate, serum lipids, and uric acid clearance in two patients treated with allopurinol

<table>
<thead>
<tr>
<th>Allpurinol (alone)</th>
<th>Allpurinol + fenofibrate combination</th>
<th>Allpurinol (fenofibrate withdrawn)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum urate (mmol/l)</td>
<td>0.40</td>
<td>0.26</td>
</tr>
<tr>
<td>Uric acid clearance (ml/min)</td>
<td>6.4</td>
<td>11.5</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>7.4</td>
<td>5.9</td>
</tr>
<tr>
<td>Serum triglycerides (mmol/l)</td>
<td>1.3</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Patient 2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum urate (mmol/l)</td>
<td>0.61</td>
<td>0.46</td>
</tr>
<tr>
<td>Uric acid clearance (ml/min)</td>
<td>8.0</td>
<td>16.4</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.4</td>
<td>4.9</td>
</tr>
<tr>
<td>Serum triglycerides (mmol/l)</td>
<td>2.3</td>
<td>2.1</td>
</tr>
</tbody>
</table>

Both, despite allopurinol treatment. Fenofibrate is an established treatment for many common lipid disorders and is unique amongst the fibrin acid derivatives because of its ability to lower serum urate by increasing renal uric acid clearance. This urate lowering potential has been demonstrated in healthy volunteers1 and in diabetic and non-diabetic patients with hyperlipedimia.2,3 To date, no studies have specifically evaluated the urate lowering effect of fenofibrate in patients with hyperuricemia receiving established treatment with allopurinol. We report three cases in which micronised fenofibrate, a single dose formulation of the drug, was initiated in patients with established gout and hyperuricemia, with and without coexisting hyperlipedimia. Two of these patients were already receiving established allopurinol treatment.

PATIENT 1
A 74 year old Chinese man had recurrent attacks of gout affecting the metatarsophalangeal joint every two to three months for the preceding three years. He had treated hypertriglyceridaemia and polygenic hypercholesterolaemia and had been taking allopurinol 300 mg daily for three months, which produced a serum urate range between 0.40 and 0.44 mmol/l. The 24 hour renal uric acid clearance was 6.4 ml/min (reference range 6–11). Treatment was started with micronised fenofibrate 200 mg daily, and three weeks later his urate had fallen by 35% to 0.26 mmol/l, with the 24 hour uric acid clearance rising to 11.5 ml/min (table 1). Alkaline phosphatase activity fell from 77 to 44 U/l, confirming compliance with the fibrate treatment. A temporary withdrawal of fenofibrate treatment for three months, which produced a serum urate of 0.39 mmol/l, resulted in an increase in urate to 0.39 mmol/l and triglycerides 2.4 mmol/l. Treatment with micronised fenofibrate was started, and three weeks later his urate was 0.34 mmol/l (a 29% reduction). Both cholesterol and triglyceride concentrations were also reduced, from 7.3 mmol/l and 1.5 mmol/l respectively, and the uric acid clearance rose from 5.8 to 11.2 ml/min. Alkaline phosphatase activity fell from 82 to 72 U/l. He continues to receive micronised fenofibrate 200 mg daily, and further attacks of acute gout have not recurred over a six month follow up period.

We have reported three cases of hyperuricaemia in association with recurrent episodes of gout, in which micronised fenofibrate was effective in further lowering serum urate and in reducing the frequency of gouty attacks. Importantly, two of these patients were already being treated with allopurinol. Total urate ejection fraction has been previously shown in patients with hyperlipedimia treated with fenofibrate,4 but this report demonstrates its efficacy specifically in patients with hyperuricaemia and gout.

The reductions in urate shown in these three patients treated with fenofibrate were of similar magnitude to those seen in patients given the drug who had hyperlipidaemia with or without type 2 diabetes and who were not receiving allopurinol treatment.5,6 The doubling in uric acid clearance, which was reversed in two of the patients when fenofibrate was withdrawn, indicates a drug-specific renal effect. The particularly large reduction in serum urate in the second patient was perhaps a little surprising, but we are certain that this was largely a fenofibrate effect because a rise in uric acid clearance was seen, together with reductions in alkaline phosphatase activity and serum lipids. Furthermore, he denied any significant lifestyle changes during this period. Importantly, none of these patients had had any adverse effect, in particular a flare of gout, while taking fenofibrate. Only the second patient wished to take a prophylactic drug against this. Each was advised to increase their fluid intake at the time, though uric acid urolithiasis has not been reported previously with fenofibrate. There has been no evidence of an adverse interaction between allopurinol and fenofibrate in the first two patients, who both continue to take this combination. Although specific adverse reactions and interactions should be borne in mind when fenofibrate is prescribed for patients with hyperuricaemia, and measures taken to prevent them considered.

Severe urate is often raised in hyperlipedimic patients, particularly those with hypertriglyceridaemia.7,8 The mechanism for the relationship is not clearly defined, though the association may arise through a number of environmental and genetic risk factors shared by hyperuricaemia and hypertriglyceridaemia, such as obesity and excessive alcohol consumption, or through a primary metabolic defect.9 In contrast, hypertriglyceridaemia has been reported to occur in up to 60% of patients with gout.10

Hyperlipedimia is common in the UK population and is a major risk factor for cardiovasculare disease. The relationship between ischaemic heart disease and serum urate is controversial. It has recently been shown that hyperuricaemia may be an independent risk factor for ischaemic heart disease,11 though other studies have not supported this observation.12 A reduction in both hyperuricaemia and serum urate might therefore be desirable in order to reduce cardiovascular risk. Fenofibrate may offer a useful dual effect in this respect, so potentially reducing the need for multiple drug treatments. This specific role for the drug is an important area in need of further study.

We have confirmed in our three cases that fenofibrate effectively lowers serum urate by a uricosuric effect. Expected reductions in lipids were also seen, suggesting a specific clinical role of this drug in the treatment of the common metabolic abnormality of coexisting hyperuricaemia and hyperlipedimia. Further, it may be considered in combination with allopurinol in patients with hyperuricaemia who still experience gout despite a lowering in their serum urate. We would encourage further studies to be performed to evaluate the role of fenofibrate alone or in combination with allopurinol in the treatment of gout and hyperuricaemia. Gout remains a common problem in the community—fenofibrate appears to be a long awaited agent with great potential for use in this condition.

A L HEBURN
Rheumatology Section,
Imperial College School of Medicine,
Hammersmith Hospital,
Du Cane Road,
London W12 0NN, UK

S A KAYE
Rheumatology Department,
Chelsea and Westminster Hospital,
Fulham Road,
London SW10 9NH, UK

M D FEHER
Lipid Clinic,
Chelsea and Westminster Hospital

Correspondence to: Dr Hepburn


www.amrheumdis.com

Effect of leeches therapy (Hirudo medicinalis) in painful osteoarthritis of the knee: a pilot study

Leeches therapy was a mainstay in conventional treatment of pain and inflammatory diseases throughout antiquity until the 20th century. There is now renewed interest in leech therapy in the field of complementary medicine. Sales of the four principal German traders have increased continuously throughout the past few years and led to an estimated 70,000 treatments (330,000 leeches sold per year, four to five used for each single treatment) yearly in Germany (Roth M, unpublished data). The majority of these treatments aim at pain reduction in regional pain syndromes, mostly for knee osteoarthritis. With the exception of its application in plastic surgery to maintain blood flow in congested skin flaps, treatment with leeches has, however, never been evaluated in clinical studies. We, therefore, conducted a non-randomised controlled pilot study to assess the onset of action and the impact of leeches therapy as an adjunctive treatment in knee osteoarthritis.

From inpatients whose main diagnosis was severe chronic back pain, we recruited over a period of three months 16 consecutive patients with primary knee osteoarthritis. All patients had persistent knee pain for more than six months and had definite radiographic signs of knee osteoarthritis without previous injury. Major exclusion criteria were treatment with anticoagulants, secondary osteoarthritis, substantial comorbidity, and intra-articular corticosteroids in the three preceding months. All patients had an in-hospital period of 14 days and received a health education programme, with focus on exercise, physiotherapy, relaxation techniques, and diet. Regular use of non-steroidal anti-inflammatory drugs was stopped throughout the study period.

After detailed information all patients were offered additional treatment with leeches. Ten patients (eight women, mean (SD) age 69 (9) years, mean body mass index (BMI) 28.0 (4.6) kg/m²) and were treated once with four leeches (Zaug GmbH, Bieberbach, Germany). Six controls (five women, mean age 68 (8) years, mean BMI 27.3 (3.0) kg/m²) did not wish to be treated with leeches and were treated only conventionally. The leeches were applied by trained doctors topically at the painful knee joint (fig 1), and monitoring was carried out according to published recommendations. The primary outcome measure was a change in total knee pain score, assessed by visual analogue scale (VAS, 0 = no pain, 10 = extremely painful) for 10 days, starting three days before treatment and, additionally, in a follow up 28 days after treatment.

In comparison with the controls, leech application led to rapid relief of knee pain (p<0.05 three days after treatment, Wilcoxon two sample test), with most effect seen within 24 hours after application and sustained and clinically relevant improvement after four weeks (p<0.05, Wilcoxon matched pairs test) in the absence of complications (table 1).

The mean length of treatment was 80 minutes, and the procedure was well accepted. There were no serious adverse effects and no local infections. Patients described the initial leech bite as slightly painful. There are several explanations for the observed treatment effect. The saliva of leeches contains a variety of substances such as hirudin, hyaluronidase, histamine-like vasodilators, collagenase, inhibitors of kalikrein and superoxide production, and poorly characterised anaesthetic and algicidal compounds." Therefore, a regional analgesic and anti-inflammatory effect by these substances enforced by hyaluronidase as well as counter-irritation might be possible. More importantly, we do not know the non-specific (placebo) effects of this unusual treatment. We observed an apparent mood enhancement during leeching which might explain the observed rapid treatment effect, but hardly explains the lasting pain relief after four weeks.

We recognise the limitations of the present study design as the non-random allocation of treatment, no assessment of functional improvement, and the small sample size. However, we regard the observed clear treatment effect as remarkable; treatment with leeches reduced pain significantly after three days and up to four weeks. The efficacy and safety of this traditional treatment in knee osteoarthritis should therefore be tested in larger randomised controlled trials.

The study was supported by Karl and Veronika Carstens Foundation, Germany.

A MICHALEN
U DEUSE
D GOBOS
Klinikum Eisen–Mitte, Department for Internal and Integrative Medicine, Am Deimelsberg 34a, D-45276 Essen, Germany
S MOEBUS
Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty, University of Essen, Hufelandstrasse 55, D-45147 Essen, Germany

Correspondence to: Privat Dozent Dr med G Dobos gustav.dobos@uni-essen.de


Clinical features of several connective tissue diseases with anti-Golgi antibody

Rodriguez et al were the first to report autoantibodies directed against the Golgi complex identified in the serum of a patient with Sjögren’s syndrome (SS). Since then, several isolated reports have described the

![Figure 1](https://example.com/figure1.png)
presence of anti-Golgi antibodies (AGAs) in several connective tissue diseases (CTDs). In addition, immunoblotting and immunoprecipitation studies have suggested that there are at least 14 different Golgi complex autoantigen and their molecular masses range from 35 to 260 kDa. However, few reports describe the association between the clinical features of CTDs and AGAs. In this letter we present a case of rheumatoid arthritis (RA) associated with AGAs and review several reported cases.

The patient was a woman born in 1939 who developed seropositive RA in 1990. She was admitted to our hospital in March 1998 because of high grade fever, cough, sore throat, chest pain, and severe arthralgia. Systemic laboratory examination disclosed no antinuclear antibody, anti-DNA antibody, or anti-Jo-1 antibody. Anti-SS-A antibody was positive. Chest computed tomography showed interstitial pneumonia with fine reticular shadow and honeycombing in both lower lobes. Physical examination showed fine crackles in both lung fields. A laboratory examination showed raised C-reactive protein (78 mg/l), serum aspartate aminotransferase (62 U/l), serum alanine aminotransferase (52 U/l), creatine kinase (236 U/l), lactate dehydrogenase (527 U/l), IgA (5.6 g/l), and IgG (26.2 g/l). Mild interstitial lymphocytic infiltration was demonstrated in a muscle biopsy specimen. Therefore, a clinical diagnosis of RA, polymyositis complicated with interstitial pneumonia was made, in addition to a suspicion of SS.

Figure 1 Indirect immunofluorescence staining of anti-Golgi antibodies just outside the nuclear membrane of Hep-2 cells with the patient’s serum. Crescent-shaped cytoplasmic organelia that surround the nuclear membrane of Hep-2 cells are clearly shown, and considered to be Golgi apparatus. Linear-shaped cytoplasmic filaments are also seen and considered to be cytokeratins.

Table 1 Characteristics of patients with connective tissue diseases in whom anti-Golgi antibodies were detected

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Age and sex</th>
<th>Background*</th>
<th>Rheumatoid factor</th>
<th>Antinuclear antibody</th>
<th>Arthritis</th>
<th>Cardiopulmonary†</th>
<th>Liver dysfunction</th>
<th>Molecular weight (kDa)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rodriguez</td>
<td>1982</td>
<td>39F</td>
<td>SS + lymphoma</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND†</td>
<td>ND</td>
<td>ND</td>
<td>1</td>
</tr>
<tr>
<td>Fritzler</td>
<td>1984</td>
<td>71M</td>
<td>SLE</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>2</td>
</tr>
<tr>
<td>Fritzler</td>
<td>1984</td>
<td>53M</td>
<td>SLE</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND†</td>
<td>ND</td>
<td>ND</td>
<td>2</td>
</tr>
<tr>
<td>Fritzler</td>
<td>1984</td>
<td>28F</td>
<td>SLE</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>2</td>
</tr>
<tr>
<td>Fritzler</td>
<td>1984</td>
<td>22F</td>
<td>SLE</td>
<td>ND</td>
<td>+</td>
<td>ND</td>
<td>ND†</td>
<td>ND</td>
<td>ND</td>
<td>2</td>
</tr>
<tr>
<td>Fritzler</td>
<td>1984</td>
<td>36F</td>
<td>SLE</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>2</td>
</tr>
<tr>
<td>Fritzler</td>
<td>1984</td>
<td>25M</td>
<td>SLE + RA</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>2</td>
</tr>
<tr>
<td>Fritzler</td>
<td>1984</td>
<td>41F</td>
<td></td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>ND†</td>
<td>ND</td>
<td>ND</td>
<td>2</td>
</tr>
<tr>
<td>Rossie</td>
<td>1982</td>
<td>75F</td>
<td>PM + SLE</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Rossie</td>
<td>1982</td>
<td>58F</td>
<td>RA</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Hong</td>
<td>1992</td>
<td>58F</td>
<td>RA</td>
<td>ND</td>
<td>+</td>
<td>ND</td>
<td>ND†</td>
<td>ND</td>
<td>+</td>
<td>4</td>
</tr>
<tr>
<td>Hong</td>
<td>1992</td>
<td>66F</td>
<td>RA</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND†</td>
<td>ND</td>
<td>+</td>
<td>4</td>
</tr>
<tr>
<td>Kooy</td>
<td>1994</td>
<td>57F</td>
<td>RA</td>
<td>ND</td>
<td>+</td>
<td>ND</td>
<td>ND†</td>
<td>ND</td>
<td>+</td>
<td>4</td>
</tr>
<tr>
<td>Griffith</td>
<td>1997</td>
<td>39F</td>
<td>Secondary SS</td>
<td>ND</td>
<td>ND†</td>
<td>ND</td>
<td>ND†</td>
<td>ND</td>
<td>+</td>
<td>7</td>
</tr>
<tr>
<td>Yang</td>
<td>2001</td>
<td>61F</td>
<td>RA + PM</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>85, 50</td>
<td>+</td>
</tr>
</tbody>
</table>

Total cases (%) 4/5 (80%) 10/14 (71%) 9/11 (82%) 6/10 (60%) 8/13 (62%)

*SS = Sjögren’s syndrome; SLE = systemic lupus erythematosus; RA = rheumatoid arthritis; PM = polymyositis.
†Cardiopulmonary parameters included pericarditis, pleuritis, and or pulmonary fibrosis.
‡ND = not described.
Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE

It is sometimes difficult to distinguish infection from disease flare in febrile patients with systemic lupus erythematosus (SLE). Chill, leucocytosis, and increased C reactive protein (CRP) are known to be markers favouring systemic lupus erythematosus (SLE). Chill, febrile period. Results are shown as means (SD) ± 0.8

We prospectively enrolled 19 patients with SLE with fever who were admitted to Seoul National University Hospital between October 1998 and April 1999. Fever was defined as an axillary temperature over 38°C. Eleven patients with inactive SLE were enrolled as controls. Blood of the febrile lupus patients was withdrawn three times: on the day of the hospital visit, and after 24 hours and 48 hours. Another sample was withdrawn two weeks after defervescence to control infection or because of a decrease in lupus activity. At the time of fever, blood cultures and other necessary cultures were performed with complete blood count, Westergren erythrocyte sedimentation rate (ESR), CRP, serum anti-dsDNA, complements (C3, C4), urine analysis, serum creatinine, and chest x-ray examination.

The patients were divided into groups on the basis of viral infection, non-viral infection, and lupus flare. Lupus flare was defined by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)1 as an increase of more than three points compared with the SLEDAI of the patient one month before the febrile period. Serum PCT was measured by an immunoluminometric assay (LUMItest, Brahms Diagnostika, Berlin). Twelve lupus patients were shown to have infection (nine non-viral, three viral infections) and seven patients with lupus flare. Non-viral infections consisted of urinary tract infection (n=3), sinusitis (n=1), tuberculosis (n=1), scrub typhus (n=1), pseudomembranous colitis (n=1), aspergillosis (n=1), and nocardiosis (n=1). Viral infections were upper respiratory infection (n=2) and gastroenteritis (n=1).

The white cell count was higher in the group with non-viral infection than in the group with lupus flare. Serum PCT increased in severe bacterial or fungal infection but does not increase, or increases only slightly, in viral infections. The purpose of this study was to evaluate the usefulness of serum PCT in febrile episodes of patients with SLE to distinguish infection from disease flare.

<table>
<thead>
<tr>
<th>Group</th>
<th>Sex (M:F)</th>
<th>Age (years)</th>
<th>ESR (nm/1st h)</th>
<th>CRP (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-viral infection (n=9)</td>
<td>1:8</td>
<td>25.6(13)</td>
<td>12.9 (8.8)*</td>
<td>82.0 (27.7)</td>
</tr>
<tr>
<td>Viral infection (n=3)</td>
<td>1:2</td>
<td>25.7(3.5)</td>
<td>5.7 (4.9)</td>
<td>60.0 (49.8)</td>
</tr>
<tr>
<td>Lupus flare (n=7)</td>
<td>0:7</td>
<td>33 (8.2)</td>
<td>3.9(1.4)</td>
<td>97.7 (31.5)</td>
</tr>
<tr>
<td>Controls (n=11)</td>
<td>1:10</td>
<td>43.2 (13.7)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p=0.015 compared with the group with lupus flare.

Figure 1 Mean procalcitonin levels during and after febrile episode. Bars denote standard error.

We are indebted to Bokyung Co and Miss Kyung Hee Lee for their help during this study.

This study was supported by a grant from Seoul National University College of Medicine, Seoul National University College of Medicine, Seoul, Korea.

Correspondence to: Dr Y W Song, Department of Internal Medicine, Seoul National University College of Medicine, Chongro-kua, Yongon-dong 28, Seoul 110-744, Korea

yosong@plaza.snu.ac.kr

References


increase in patients with Wegener’s granulomatosis upon disease aggravation but increased with combined infection. Our study is the first to observe serum PCT changes in lupus patients with fever and defervescence prospectively. In our study lupus patients with bacterial or fungal infection had higher serum PCT levels than those with viral infections and a higher level than the controls. We tried to determine the serum PCT changes during the febrile period by measuring samples. Serum PCT in the group with non-viral infection tended to increase continuously or rise gradually in the early febrile period (fig 1). The PCT values varied among the non-viral group and serious infections, such as aspergillus pneumonia, showed higher values than urinary infection or sinusitis (data not shown). The pitfalls of PCT as a marker for infection are that it may not increase or increase only slightly in viral infection. Our study showed that there was no difference between the serum PCT of the group with viral infection and the control group.

CRP is useful for detecting and differentiating infections in lupus. CRP rises earlier and is more sensitive than ESR. In this study, CRP tended to increase in the case of non-viral infection, compared with viral infection or lupus flare, but this did not reach statistical significance. Our results indicate that during the early febrile period, serum PCT increased significantly in patients with SLE with non-viral infection compared with patients with lupus flare. Serum PCT decreased after defervescence. These results suggest that serum PCT helps in detecting bacterial or fungal infections during the early febrile period in SLE.
Matters arising, Letters

**Effect of daily corticosteroid treatment on CRP response to hip or knee replacement in patients with RA**

Serum C reactive protein (CRP) is an acute phase reactant which may be continuously increased in patients with persistently active rheumatoid arthritis (RA), or raised only temporarily to a high concentration for a few days as a normal response to uncomplicated hip or knee replacement in patients with osteoarthritis or RA. CRP usually decreases in patients with RA when inflammatory activity is treated with daily low dose corticosteroid. This prompts the question whether the CRP response to hip or knee replacement is decreased in patients with RA taking a daily low dose of oral corticosteroid compared with those not taking corticosteroid. This is an important issue because CRP is used as an index to indicate postoperative complications. In this letter we compare the CRP response to hip or knee replacement in two groups of patients with RA: those taking and those not taking oral low dose corticosteroid.

Sixty patients (47 women, 13 men) fulfilling the American Rheumatism Association 1987 criteria for RA, treated at the Rheumatism Foundation Hospital, Heinola, in 1999, underwent hip or knee replacement. Fifty two patients were seropositive. The group receiving prednisolone comprised 44 patients, mean age 62 (SD 8.2) years. The prednisolone doses were as follows: four patients received <5 mg daily, 37 had 5–10 mg daily, and three had 12.5–30 mg daily. The patient group not receiving prednisolone comprised 16 patients, mean age 59 (13.4) years.

The CRP concentration was measured by the Randox, United Kingdom, immunoturbidimetric assay. The magnitude of the CRP response was measured by assessing the difference between measurements taken preoperatively and during the first one to two days postoperatively (the time of the peak CRP level) in both patient groups. The CRP responses in the respective groups were compared and statistically evaluated with the Mann-Whitney U test. In the group not receiving prednisolone the preoperative median CRP level was 12 (interquartile range [IQR] 5–26) mg/l, and at day 1 or 2 postoperatively the median CRP had risen to 80 (IQR 53–112) mg/l. In the group in which patients were taking prednisolone the preoperative median was 14 (IQR 6–38) mg/l, the postoperative median 62 (IQR 41–100) mg/l. The difference in CRP response to the operation between the groups was not significant, p=0.15 (fig 1). None of the patients had bacterial infection or substantial haematoma after the operation.

The rise in CRP concentration in response to hip or knee replacement was slightly, but not significantly, smaller in patients with RA receiving than in those not receiving prednisolone. Increased CRP concentration was a normal phenomenon in the first few days after hip or knee replacement in these patients with RA and was not altered by low dose prednisolone treatment. This study affords no information as to the CRP response in the presence of postoperative complications, because no such case was encountered. However, we recommend further measures if the CRP concentration remains raised for several days postoperatively and does not decrease steadily.

K LAIHO
H MÄENPÄÄ
H KAUTTAINEN
M KAUPPI

Rheumatism Foundation Hospital
Heinola, Finland

Correspondence to: Dr K Laiho, Rheumatism Foundation Hospital, FIN-18120 Heinola, Finland
markku kauppi reuma fi

**Lumbar spondylodiscitis secondary to *Enterobacter cloacae* septicaemia after extracorporeal shock wave lithotripsy**

Infections of the lumbar spine may affect either the intervertebral disc or the vertebral body. Most infections of the intervertebral disc occur as an extension of vertebral osteomyelitis or direct inoculations during diagnostic or surgical procedures, or include urinary tract infections and septicaemia. This paper reports a case of L5–S1 spondylodiscitis secondary to *Enterobacter cloacae* septicaemia after extracorporeal shock wave lithotripsy (ESWL).

A 52 year old man presented with side pain, pollakiuria, haematuria, and nocturia. He had been treated with ciprofloxacin for acute pyelonephritis and nephrolithiasis as an outpatient. One week later, the patient was admitted to hospital by the urology department with symptoms of left side pain, fever, chills, shaking, and dysuria. Right renal and right ureter distal lithiasis and right hydropnephrosis due to the lithiasis were diagnosed. One week after ESWL the patient was sent to the physical medicine and rehabilitation clinic with chills, shaking, high fever, and low back pain complaints. Lumbar movements were found to be restricted. There was an increase in severe pain at rest. The patient could not stand or walk. No neurological deficit was present. Body temperature was 39°C, pulse 110 beats/min, blood pressure 130/70 mm Hg, breathing 20 breaths/min.

Laboratory findings were as follows: haemoglobin 133 g/l, packed cell volume 0.31, white blood cells 18×10⁹/l, platelets 316×10⁹/l, erythrocyte sedimentation rate 110 mm/1st h, anti-streptolysin O 25 IU, C reactive protein 12.3 mg/l, rheumatoid factor negative. Urea was 14 mg/dl, creatinine 170 µmol/l. Glucose and electrolytes were normal and serum aspartate aminotransferase was 80 U/l, serum alanine aminotransferase 44 U/l, lactate dehydrogenase 321 U/l, total bilirubin 22 µmol/l, direct bilirubin 10 µmol/l. A considerable number of leucocytes and erythrocytes were noticed in urine microscopy. *Enterobacter cloacae* was isolated from blood and urine. The isolated pathogen was sensitive to ceftriaxone and amikacin.
Figure 1 shows magnetic resonance imaging (MRI) pictures obtained two weeks after the septicemia. Amikacin (1500 mg/day) and indometacin (150 mg/day) were given, but amikacin was stopped because nephrotoxicity developed after seven days of treatment. Later, ceftriaxone 2 g twice a day was given for one week, and then maintained at 1 g/day for three months. The patient used a lumbosacral support.

The clinical and laboratory findings of the patient improved and pain was relieved after a two month rehabilitation programme. The control MRI findings obtained 27 months later showed degeneration of the L5-S1 intervertebral disc and adjacent vertebral corpus end plates. Grade 1 spondylolisthesis is the sequel to the infection. Lumbar spondylodiscitis has not recovered after two years’ follow-up.

Staphylococcus aureus is reported as the major agent of spondylodiscitis. Streptococcus viridans, Streptococcus pyogenes, Salmonella spp, Enterococcus spp, Pseudomonas aeruginosa, and Brucella spp are other possible causative agents. In most cases, isolation of an agent is difficult. In a limited number of cases an agent may be isolated in biopsy materials or in blood.

We found two reported cases of spondylodiscitis caused by Enterobacter cloacae. Generally, S. aureus is the causative agent. However, Salmonella enteritidis, Candida albicans, Streptococcus spp, and Enterococcus spp are rare isolated pathogens. In our case, acute pyelonephritis was diagnosed before spondylodiscitis. Furthermore, worsening of the symptoms after ESWL seems important. Haematoma, contusion, petechial haemorrhagic focuses in the liver are reported as side effects of ESWL. Whether the spine infection was present before lithotripsy is not clear to us. There was insufficient time between the lithotripsy and diagnosis of the spine infection. Thus we think that the infection was present before the lithotripsy. ESWL may cause the spread of vertebral osteomyelitis or acceleration of sepsis. Because the case seems to originate through the haematogenous route, it may be more appropriate to state that it represents an extension of vertebral osteomyelitis.

Spinal infections should always be considered in severe back and lumbar pain. The patients should be monitored in a clinical and laboratory setting after invasive therapeutic procedures. Prophylactic antibiotic treatment should be given in an ESWL procedure.

Rheumatic pneumonia

Rheumatic pneumonia (RP) is a well described and poorly understood complication of acute rheumatic fever (ARF). It has been reported for more than a century and it has been traditionally associated with a high mortality rate. However, the existence and specificity of primary pulmonary lesions has remained controversial, because similar features may be seen in ARF with complicating congestive failure or uraemia. We report a case of RP that was successfully treated with steroids.

An 18 year old man was admitted to our hospital because of a 10 day history of fever, malaise, and dry cough. The patient had had ARF with carditis at age 7, which resolved without sequelae. A tonsillectomy was performed three years later. Since then, he had received a benzathine penicillin G injection monthly until three years before his actual admission. On admission, physical examination disclosed a temperature of 38.5°C, respiratory rate of 26/min, and rales were heard at the left lower lung. The rest of the examination was unremarkable.

Laboratory values were white blood cells 14.3×10³/l, with 80% neutrophils and 9% band cells, haemoglobin 132 g/l, and platelets 410×10³/l. The erythrocyte sedimentation rate was 90 mm/1st h. Urine analysis, coagulation studies, renal and hepatic function tests, and arterial blood gas value analysis during room air breathing were normal. A chest x ray examination showed an ill-defined and non-homogeneous area of consolidation at the left lower lobe with a normal cardiac silhouette. As there was a clinical suspicion of pneumonia, acquired in the community, intravenous cefuroxime (750 mg three times a day) and oral roxithromycine (150 mg twice daily) were given.

On the fourth day after admission to hospital, fever and tachypnoea persisted. Consolidation of the air space in the posterior segment of the left lower lobe and pleural effusion were seen on chest x ray examination and thoracic computed tomography (fig 1). Thoracentesis yielded a serous fluid containing 1.2×10³ leucocytes/l, with 70% neutrophils, glucose 1.4 mmol/l, protein 27 g/l.
and lactate dehydrogenase 477 IU. Doppler echocardiography showed a posterior pericardial effusion without any other abnormality. Bronchoscopic examination showed inflammation changes in left lower bronchi. There were no neoplastic cells in bronchoalveolar lavage specimens. Serial serological tests for Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella species, cytomegalovirus, and Epstein-Barr virus were negative. Tests for antineutrophil cytoplasmic antibodies, rheumatoid factor, and antinuclear antibodies were negative, and the serum level of angiotensin converting enzyme was normal.

On the 14th day after admission to hospital the patient developed arthritis at the left knee and the right wrist. Arthrocentesis showed a turbid fluid which contained 15.2×10^3 leucocytes/μl and glucose 1.3 g/l; no crystals were seen. Titres of antistreptolysin O and C reactive protein were 400 Todd units (normal <200) and 1.20 g/l, respectively. Blood, sputum, pleural fluid, bronchoalveolar lavage, and joint effusion repeated cultures were negative, and no acid fast bacilli were seen. Erythema and induration occurred at the site of skin tests with streptococcal antigens. The antibiotic treatment was discontinued and acetylsalicylic acid (1.5 g four times a day) was started. A dramatic improvement in fever and arthritis occurred, though the radiological lesion remained unchanged. A biopsy of a lymph node showed confluent nodular lesions. V

Multiple radiological patterns have been described, including consolidation, diffuse bilateral and migratory infiltrates, pleural effusion, and confluent nodular lesions. A pathological examination shows no unique lung lesions in ARF, and the most commonly reported pulmonary findings have been vascular haemorrhage, acute bronchopneumonia, organising fibrinous oedema, interstitial inflammatory exudates, inflammation and necrosis of septa, arteriolitis, and globular tufts of intraalveolar fibrous tissue, so-called Masson bodies. It may be difficult to separate the contribution of the heart failure or uraemia to the RP by itself. Because of the lack of specific criteria, RP remains an exclusion diagnosis.

Our patient satisfied the updated Jones criteria for the diagnosis of ARF. The absence of response to antimicrobial treatment, the histological findings, and the response to anti-inflammatory treatment favoured a diagnosis of RP. Despite the fact that salicylates have been advocated in the management of RP, steroids seem to be the most suitable treatment. None the less, deaths have occurred despite the use of this treatment.

Table 1 Summary of cases reports of rheumatic pneumonia over the past two decades

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age/sex</th>
<th>Previous ARF</th>
<th>Major criteria</th>
<th>Cardiac failure</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>13/M</td>
<td>No</td>
<td>Carditis</td>
<td>Yes</td>
<td>Hydrocortisone</td>
<td>Died</td>
</tr>
<tr>
<td>6</td>
<td>14/F</td>
<td>Yes</td>
<td>Carditis</td>
<td>Yes</td>
<td>Pyrazolined</td>
<td>Favourable</td>
</tr>
<tr>
<td>7</td>
<td>14/M</td>
<td>Yes</td>
<td>Arthritis</td>
<td>Yes</td>
<td>Prednisone</td>
<td>Favourable</td>
</tr>
<tr>
<td>8</td>
<td>10/M</td>
<td>No</td>
<td>Carditis</td>
<td>No</td>
<td>Aspirin</td>
<td>Favourable</td>
</tr>
<tr>
<td>9</td>
<td>10/F</td>
<td>No</td>
<td>Carditis</td>
<td>Yes</td>
<td>Salicylates (initial)</td>
<td>Died</td>
</tr>
<tr>
<td>4</td>
<td>19/M</td>
<td>No</td>
<td>Carditis</td>
<td>Yes</td>
<td>Steroid</td>
<td>Prednisone</td>
</tr>
<tr>
<td>Present report</td>
<td></td>
<td>Yes</td>
<td>Arthritis</td>
<td>No</td>
<td>Aspirin (initial)</td>
<td>Favourable</td>
</tr>
</tbody>
</table>

There is mounting evidence that early disease modifying treatment improves the outcome in patients with rheumatoid arthritis (RA) and that treatment should begin before the disease is established and irreversible damage has occurred. The evidence has led to the development of “early synovitis clinics” in many rheumatology units to fast track appropriate patients. Early referral for specialist advice has been shown to be associated with improved health and physical function, with the concept of early treatment of RA shortening observation periods before referral in general practice. A shortened observation time is important as Irvine et al showed that 73% of patients waiting more than a year from the onset of symptoms already had radiological evidence of erosive change.

Despite the improved observation times, there are few published data showing whether referrals to early synovitis clinics are appropriate. We reviewed all referrals (n=156) to our early synovitis clinic at the Royal Victoria Hospital, Belfast, which was established in January 1999, to determine the proportion which were inappropriate. Referrals were considered inappropriate if they could be classified within a broad based category of inflammatory arthritis. We felt a broad based approach was necessary to identify patients with RA early in the disease course. Referral guidelines to the early synovitis clinic were circulated to all general practitioners in the catchment area of the hospital (population 600 000) every three months. The information was also disseminated by the local medical press and by presentations at general practitioner meetings.

Fifty four per cent (n=84) of the 156 patients were classified as having inflammatory arthritis. Of these patients, 33 were diagnosed as RA and disease modifying treatment was started. The other diagnoses within the inflammatory arthritis group included psoriatic arthritis, reactive arthritis, ankylosing spondylitis, seronegative arthritis, systemic lupus erythematosus, primary Sjögren’s syndrome, and crystal arthritis. Despite the educational strategies outlined above, a large percentage of referrals were inappropriate. Forty six per cent (n=72) of patients did not have inflammatory arthritis. Of these patients, 35 had fibromyalgia, 28 had osteoarthritis, and nine had another diagnosis within the category of soft tissue rheumatism.

The median time from symptom onset to referral was eight weeks and the median time from arrival of the referral letter to attendance at the early arthritis clinic was four weeks. These results suggest that although the message about early referral appears to have been successful there were a large number of inappropriate referrals.
Factors contributing to inappropriate referrals include:
- The low priority of musculoskeletal disorders in undergraduate training, resulting in poor skills in recognising signs and symptoms of inflammatory arthritis
- The opportunity for faster access to a specialty with long waiting lists
- The broad based referral guidelines which were designed to obtain maximum sensitivity for patients with early RA

To maximise valuable clinic time for patients with early RA and improve the proportion of appropriate referrals we suggest that increased emphasis should be given to the importance of recognition of inflammatory arthritis in undergraduate and postgraduate medical education. The exploration of new methods of triage in primary care groups by general practitioners with a special interest in rheumatology, or by specialist rheumatology nurses, may also help to improve referrals.

P A COURTNEY
G D WRIGHT
Department of Rheumatology,
Royal Victoria Hospital,
Belfast, N Ireland

Correspondence to: Dr P Courtney, Department of Rheumatology, Musgrave Park Hospital, Stockman's Lane, Belfast BT9 7BJ, N Ireland
p.pa.courtney@talk21.com

Anti-dsDNA antibodies associated with acute EBV infection in Sjögren’s syndrome

The role of viral infection in the pathogenesis of autoimmune diseases is not clear. Some authors have suggested a role for herpes viruses and retroviruses in the pathogenesis of systemic rheumatic diseases, whereas others have produced evidence against this idea. In this report we present a case in which an association was found between Epstein-Barr virus (EBV) infection and anti-dsDNA antibodies in a patient with Sjögren’s syndrome.

A 28 year old woman was diagnosed with Sjögren’s syndrome. The clinical presentation included diffuse myalgias, tiredness, and intermittent respiratory complaints. Electrophones showed polyclonal hypergammaglobulinaemia. Antibody testing by indirect immunofluorescence on HEp-2 cells (Immunocconcepts, Sacramento, CA) showed a fine speckled nuclear pattern. The antibodies were identified as anti-Ro/SS-A antibodies by counterimmunoelectrophoresis. No anti-double stranded DNA (anti-dsDNA) antibodies were present (Crittibida luciae assay; Immunocconcepts). Four years after the diagnosis of Sjögren’s syndrome, the patient had an acute EBV infection with persistent tiredness, icterus, and hepatosplenomegaly. The EBV infection was documented by positive heterophile antibodies and the presence of IgM (titre 1/32) and IgG (titre 1/256) antibodies to EBV viral capsid antigen. The antibodies to early antigens were negative (<1/8). The patient did not have IgM rheumatoid factor, which excluded the possibility of a false positive IgM-viral capsid antigen test induced by the presence of rheumatoid factor. Neither antiviral capsid antigen antibodies nor anti-early antigen antibodies had been found one year before the patient presented with the EBV infection. The Crititibida luciae test was negative two months before the EBV infection. Three months and eight months after the acute infection, respectively, the Farr assay (Ortho Clinical Diagnostics, Amersham, UK) and the Critidhida luciae assay disclosed anti-dsDNA antibodies. The patients showed no progressive disease and did not develop signs of systemic lupus erythematosus.

The association between EBV and anti-dsDNA antibodies in the case presented here indicates a possible role of the virus in the generation of anti-dsDNA antibodies. The formation of anti-dsDNA autoantibodies may result from the activation of specific B lymphocyte clones or from an imbalance in the regulation of the immune system due to EBV infection. This is consistent with the finding that EBV transformed B cells can produce IgG antibodies with specificity for dsDNA, and with the suggestion that EBV infection may be a causative factor in lupus.

E Y PADALKO
X BOSSUYT
Laboratory Medicine, Immunology,
University Hospitals Leuven,
Herestraat 49,
3000 Leuven, Belgium

Correspondence to: Dr Bossuyt

This work was presented at the 52nd AACC annual meeting, San Francisco, CA in June 2000 and has been published in abstract form in Clin Chem 2000;46(suppl 6):A44.